anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
We aimed to study atrophy and glucose metabolism of the cholinergic basal forebrain in non-demented mutation carriers for autosomal dominant Alzheimer's disease (ADAD). We determined the level of evidence for or against atrophy and impaired metabolism of the basal forebrain in 167 non-demented carriers of the Colombian PSEN1 E280A mutation and 75 age- and sex-matched non-mutation carriers of the same kindred using a Bayesian analysis framework. We analyzed baseline MRI, amyloid PET, and FDG-PET scans of the Alzheimer's Prevention Initiative ADAD Colombia Trial. We found moderate evidence against an association of carrier status with basal forebrain volume (Bayes factor (BF10) = 0.182). We found moderate evidence against a difference of basal forebrain metabolism (BF10 = 0.167). There was only inconclusive evidence for an association between basal forebrain volume and delayed memory and attention (BF10 = 0.884 and 0.184, respectively), and between basal forebrain volume and global amyloid load (BF10 = 2.1). Our results distinguish PSEN1 E280A mutation carriers from sporadic AD cases in which cholinergic involvement of the basal forebrain is already detectable in the preclinical and prodromal stages. This indicates an important difference between ADAD and sporadic AD in terms of pathogenesis and potential treatment targets.
This is a single-center, randomized controlled trial to test the effects of a novel neuromodulation program on balance performance and neuroplasticity in individuals with iSCI. Participants will be randomly assigned to 2 equal groups labeled as (1) FES with VFT, and (2) combined neuromodulation with VFT. They will complete 8 training sessions over 4 weeks (2 sessions/week). For the FES with VFT group, participants will receive visual feedback regarding their center of pressure location during four games with varying levels of difficulty and FES will be applied bilaterally to SOL and TA via a closed-loop system. Each exercise will be completed 3 times per training session. For the combined neuromodulation with VFT group, the sub-motor threshold, open-loop TSCS will be coupled with closed-loop FES of ankle muscles during VFT. For this purpose, 2 electrical stimulators, one for each leg will stimulate SOL and TA muscles bilaterally while open-loop tonic lumbar TSCS will be applied at an intensity producing paresthesia in most of the lower-limb dermatomes. The range of FES stimulation intensity will vary between the minimal contraction threshold and 80% of the maximal tolerable threshold for each participant during games depending on the instant location of the participant's center of pressure and the location of the desired target during the game. All dependent variables will be assessed prior, immediately after, and 6-weeks after the end of intervention.
BACKGROUND: Early postoperative mobilization is important for enhanced recovery but can be hindered by orthostatic intolerance. However, study on postoperative orthostatic intolerance in thoracoscopic lung resection is limited. Thus, this investigation aims to examine the prevalence and variables contributing to orthostatic intolerance on the first day following thoracoscopic lung cancer resection.
METHODS: A prospective observational study was conducted from February 01 to May 05, 2023, at the First Affiliated Hospital of Chongqing Medical University. Typically, 215 subjects subjected to thoracoscopic lung resection were enrolled in this study. Their general information, disease, and treatment information were collected, and the occurrence of orthostatic intolerance was recorded.
RESULTS: Typically, 64 patients (29.77%) demonstrated orthostatic intolerance during early mobilization, and 43.75% failed to walk. The prevalence of nausea, dizziness, and impaired vision was 60.94%, 92.19%, and 25.00%, respectively, and no patient experienced syncope. The factors shown to be independently linked with orthostatic intolerance were being female (OR = 2.98, 1.53 to 5.82) and high pain level during sitting (OR = 2.69, 1.79 to 4.04). Individuals with orthostatic intolerance had a longer postoperative hospital stay with a mean of 5.42 days against 4.25 days (p = 0.003).
CONCLUSIONS: Orthostatic intolerance was prevalent following thoracoscopic lung cancer resection and affected patients' capability to mobilize and prolonged postoperative hospitalization. Being female and having high pain levels during sitting were identified as independent factors for orthostatic intolerance. This suggests that more emphasis should be given to risky patients, and for these groups, we may optimize pain management to adjust the risk of emerging orthostatic intolerance, facilitating early mobilization and early postoperative rehabilitation.
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a nonsteroidal anti-inflammatory drug may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, hypovolemia, heart failure, liver dysfunction, salt depletion, those taking diuretics and angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), and the elderly. Discontinuation of nonsteroidal anti-inflammatory drug therapy is usually followed by recovery to the pretreatment state (see ). WARNINGS: Advanced Renal Disease
Ischemia-reperfusion injury (IRI) is an inevitable pathophysiological phenomenon in kidney transplantation. Necroptosis is an undoubtedly important contributing mechanism in renal IRI. We first screened differentially expressed necroptosis-related genes (DENRGs) from public databases. Eight DENRGs were validated by independent datasets and verified by qRT-PCR in a rat IRI model. We used univariate and multivariate Cox regression analyses to establish a prognostic signature, and graft survival analysis was performed. Immune infiltrating landscape analysis and gene set enrichment analysis (GSEA) were performed to understand the underlying mechanisms of graft loss, which suggested that necroptosis may aggravate the immune response, resulting in graft loss. Subsequently, a delayed graft function (DGF) diagnostic signature was constructed using the Least Absolute Shrinkage and Selection Operator (LASSO) and exhibited robust efficacy in validation datasets. After comprehensively analyzing DENRGs during IRI, we successfully constructed a prognostic signature and DGF predictive signature, which may provide clinical insights for kidney transplant.
Scrub Typhus Patients (STP, n=60) Cohort. Blood samples will be collected at baseline (the day of presentation to hospital), 2 weeks later in hospital, 12 weeks after baseline at the clinic visit and 1 year later. Data on clinical presentation and relapses will be recorded. Eschar swab specimens and a non-invasive specimen of the dark crust will be also collected from STP group on the day of enrollment.
Compositions and method for destroying biological agents such as toxins are provided wherein the substance to be destroyed is contacted with finely divided metal oxide nanocrystals. In various embodiments, the metal oxide nanocrystals have reactive atoms stabilized on their surfaces, species adsorbed on their surfaces, or are coated with a second metal oxide. The desired metal oxide nanocrystals can be pressed into pellets for use when a powder is not feasible. The methods of the invention are safe for humans, equipment, and the environment, and provide for decontamination of warfare sites, of equipment exposed to the contaminant, and of soil, water, and air having been exposed to the contaminant. Preferred metal oxides for the methods include MgO, CaO, TiO2, ZrO2, FeO, V2O3, V2OS, MN2O3, Fe2O3, NiO, CuO, Al2O3, ZnO, and mixtures thereof. Preferred coating metal oxides include oxides of metals selected from the group consisting of Ti, V, Fe, Cu, Ni, Co, Mn, Zn, and mixtures thereof. Preferred reactive atoms include halogens and Group I metals, and preferred species include SO2, NO2, and ozone.
Participants with a history of SARS-COV-2 infection and developed long term sequalae associated with their neurologic system: brain fog, confusion, etc.. This is an experimental arm of the study. Participants will complete an ethnic survey, medical history survey and undergo two blood draws.
The invention discloses an application of pigeonpea leaf extract and monomer components thereof in preparing xanthine oxidase inhibition drugs. It has been found that the ethyl acetate, acetone, methanol, and n-hexane extract of Cajanus cajan leaf have inhibitory activity on xanthine oxidase, wherein the ethyl acetate extract has optimal inhibitory activity, and IC  50  Is 72.83 mug/mL. In addition, the monomer active substance, namely, cajanin A in cajan has inhibitory activity on xanthine oxidase and IC thereof  50  8.10. Mu.g/mL, whereas the cajanin C inhibitory activity was not apparent. However, the cyclized product DT-10 of cajanin C isopentenyl has remarkable xanthine oxidase inhibition activity and IC thereof  50  4.63. Mu.g/mL, and the positive control allopurinol IC  50  Only 7.53. Mu.g/mL. Therefore, the cajan leaf extract and the monomer component thereof can be used for preparing xanthine oxidase inhibiting medicines or medicines for preventing or treating diseases related to xanthine oxidase.
Fibroblast growth factor 21 (FGF21), a well-known regulator of metabolic disorders, exhibits the potential to prevent renal fibrosis by negatively regulating the transforming growth factor β (TGF-β)/Smad3 signaling pathway. Gemigliptin and other dipeptidyl peptidase-4 inhibitors are frequently used for the management of patients with type 2 diabetes. However, the protective effect of gemigliptin against renal fibrosis, particularly its potential to upregulate the expression of FGF21, remains incompletely understood. This study assessed the renoprotective effects of gemigliptin against TGF-β-induced renal fibrosis by enhancing the expression of FGF21 in the cultured human proximal tubular epithelial cell line HK-2. Treatment with FGF21 effectively prevented TGF-β-induced renal fibrosis by attenuating the TGF-β/Smad3 signaling pathway. Similarly, gemigliptin exhibited protective effects against TGF-β-induced renal fibrosis by mitigating TGF-β/Smad3 signaling through the upregulation of FGF21 expression. However, the protective effects of gemigliptin were blocked when FGF21 expression was knocked down in TGF-β-treated HK-2 cells. These results indicate that gemegliptin has the potential to exhibit protective effects against TGF-β-induced renal fibrosis by elevating FGF21 expression levels in cultured human proximal tubular epithelial cells.
807,955. Artificial teeth. DENTISTS' SUPPLY CO. OF NEW YORK. July 20, 1955 [Sept. 1, 1954], No. 21058/55. Class 81 (2). A porcelain artificial tooth is made by disposing raw porcelain dough around an anchorage made essentially of palladium which has been treated to render it substantially gas free, making the dough into a raw tooth biscuit having an opening extending to the anchorage, firing the biscuit to fuse the porcelain particles to each other and the anchorage while certain surfaces are exposed to the firing atmosphere, placing one end of a pin and solder into the opening in contact with the certain surfaces and subjecting the assembly to a temperature sufficient to decompose any palladium oxide and melt the solder to connect the pin and anchorage firmly together. The anchorage 12 which contains 86-100 per cent palladium is cup-shaped and is disposed on a moulding post secured to a mould which is charged with raw porcelain dough consisting of pulverized feldspar and organic binding agents. The mould, dough and anchorage are subjected to preliminary baking at 500-600 F. to produce a raw tooth biscuit. The moulding post is then removed and the raw tooth biscuit fired at a temperature of 2250-2300 F. which fuses the porcelain and produces a layer of palladium oxide on the exposed inner surface of the anchorage 12. A pin 22, made of nickel plated with gold or gold alloy, and fluxed silver solder 24 are then introduced into the anchorage 12, the assembly being then subjected to a temperature of 1450  F. which decomposes the palladium oxide and effects a firm soldered joint. Small quantities of silver, gold, platinum, indium, rhodium or ruthenium or alloys thereof may be alloyed with the palladium. The palladium or palladium alloy used is previously process-annealed in a gaseous atmosphere to render it gas free.
The present application provides a starch-indole-acid derivative, a preparation method therefor, and a use thereof and relates to the technical field of modified starch. The starch-indole-acid derivative refers to esterified starch generated by starch undergoing an esterification reaction together with indole acid under the action of a condensing agent and a base. The derivative has high resistance and can resist degradation in the stomach and small intestine. After reaching the colon, the derivative can be fermented by intestinal flora to release indole acid, which is beneficial to intestinal health. Compared with traditional administration methods such as gavage and intraperitoneal injection, the described means has significant advantages and can significantly increase the content of indole acid in colon and hepatic portal blood. In addition, indole acid can activate aryl hydrocarbon receptors to play an immunomodulatory role, which can be combined with the regulatory effect of starch releasing short-chain fatty acids by undergoing fermentation by intestinal flora, providing a product that synergistically exerts immune regulatory effects by means of multiple immune system signaling pathways.
Initial participant positioning for gliding will be : lying in supine, shoulder at approximately 90 of abduction, wrist in neutral, elbow at 90 flexion and head/neck neutral. From this starting position, participants actively and simultaneously will perform extension of the elbow (to 45) and ipsilateral neck flexion (to approximately 45) and then returned to 90 of elbow flexion and 45 of contralateral neck flexion while maintaining the shoulder at 90 abduction. According to Silva et al., (2014) this combination of movements was the one that promoted the greatest excursion of the median nerve (10.2 mm) . For gliding, four series of 10 movements at a rhythm of approximately 6 s per cycle and 1-min rest between series was performed.
Participants will receive pembrolizumab 200 mg PLUS MK-4830 800 mg. Both pembrolizumab and MK-4830 will be administered IV Q3W for up to 35 administrations (up to \~2 years).
Malaria currently represents one of the most prevalent infections in tropical and subtropical areas throughout the world. Each year, malaria affects around 300 million people and kills 1 to 3 million people in developing countries. The widespread occurrence and the growing incidence of malaria are a consequence of the increasing numbers of drug-resistant parasites and insecticide-resistant parasite vectors. Other factors include environmental and climatic changes, civil disturbances and increased mobility of populations. It is hypothesized that the Ad35.CS.01 vaccine will prevent the Plasmodium (P.) falciparum parasite, which causes malaria, from entering and developing within the liver of those who become infected. Ad35.CS.01 would therefore be expected to reduce malaria-attributable morbidity and mortality. The purpose of this phase I, randomized, controlled, dosage-escalation trial is to evaluate the immunogenicity, safety, and reactogenicity of an Adenovirus Type 35 based circumsporozoite malaria vaccine in 72 healthy adults, 18 to 45 years of age, in the United States. Subjects will be randomized in a 5:1 ratio to receive 3 doses of the Adenovirus Type 35 circumsporozoite malaria vaccine (Ad35.CS.01) or normal saline placebo control by the intramuscular route at 0, 1 and 6 months. The safety, reactogenicity, and immunogenicity of ascending dosages of the vaccine will be assessed. Fifteen subjects will receive vaccine at each of the following dosage levels: 10\^8 viral particles (vp)/milliliters (ml), 10\^9 vp/ml, 10\^10 vp/ml and 10\^11 vp/ml with 3 subjects receiving control at each of these dosage levels. Dosage escalation will proceed only after review of the safety data by the Safety Monitoring Committee of the prior dosage level. The primary objective is to assess the safety and reactogenicity of ascending dosages of Adenovirus Type 35 based circumsporozoite malaria vaccine among healthy subjects given in 3 intramuscular doses at 0, 1 and 6 months. The secondary objective is to evaluate the immunogenicity of the Adenovirus Type 35 based circumsporozoite malaria vaccine through performance of Humoral Immune Assays \[ELISA (enzyme-linked immunosorbent assay)\] for antibodies to circumsporozoite antigen and Adenovirus Neutralization Assay for neutralizing antibodies to Adenovirus type 35) and Cellular Immune Assays \[enzyme-linked immunosorbent spot (ELISPOT) and Flow Cytometry\] for circumsporozoite (CS)-specific cluster of differentiation (CD)4+ and CD8+ T cell responses.
The insert device is for attachment either to natural tissue or a prosthetic device, and delivers a prescribed dosage of energy to targeted tissue. The insert device includes an energy-source material within the insert device that delivers the prescribed dosage of energy to the targeted tissue, while minimizing exposure of nontargeted tissue. The targeted tissue has a known radio-response profile and is adjacent to the targeted tissue. The energy-source material in combination with the prosthetic device defines an actual energy-delivery distribution field. The energy-delivery distribution field has a configuration similar to the known profile of the targeted tissue. The prescribed dosage of energy is applied from energy-source material within the insert device and directed to the targeted tissue. The prescribed energy dosage is determined by using known physics characteristics of the energy-source material, and by the placement of the energy-source material relative to the targeted tissue. The implant system reduces any occurrence of heterotopic ossification caused by the implant, inhibits growth or migration of benign or malignant living cells, and minimizes or even eliminates infectious processes or delayed keloid or scar formation induced from surgical placement of a functional prosthesis or fixation device, in tissue within or about the device due to its targeted radiation effects.
Group 3 (Young adults aged 18-55 years - CVXGA1 - High Dose, prior receipt of two or more doses of COVID mRNA vaccine (Pfizer Comirnaty® or Moderna Spikevax™) at least 5 months prior to study enrollment. Prior COVID infection allowed if occurring at least 5 months prior to study enrollment).
A brief, individualized, three-session parent training that exists of two (bi)weekly individually tailored training sessions of 120 minutes, and a third session of 60 minutes. Parents and children may receive care as usual as well. Care as usual may include all mental health care that is usually provided within or outside (e.g., at a child mental healthcare institution or at school) the general practitioners practice, except from pharmacological treatment for children's behavioral difficulties and/or behavioral parent training/support, up until the first posttreatment assessment (T1). Care as usual can also imply that there is no support or treatment.
Patients in the digital preoperative assessment group are asked to complete an electronic screening questionnaire through the digital patient portal of the hospital. The questionnaire was designed by the anesthetic department physicians and consisted of 50 health related questions. Through the same digital patient portal, patients have access to animated instructional videos that provides information on anesthetic techniques, preoperative lifestyle advises and procedures around the upcoming surgery. The videos can be reviewed at any desired moment in time. A telephone appointment is scheduled solemnly to decide on the anesthesia technique and obtain informed consent since this process was technically not available in the electronic portal. Physicians were thoroughly instructed not to provide more information or answer questions. Patients are instructed to complete the electronic screening questionnaire and assess the animated videos before the scheduled appointment with the physician.
Standard tests for verification of adrenal responsiveness to corticotropin may utilize as much as 80 units as a single injection or one or more injections of a lesser dosage. Verification tests should be performed prior to treatment with corticotropins. The test should utilize the route(s) of administration proposed for treatment. Following verification dosage should be individualized according to the disease under treatment and the general medical condition of each patient. Frequency and dose of the drug should be determined by considering severity of the disease, plasma and urine corticosteroid levels and the initial response of the patient. Only gradual change in dosage schedules should be attempted, after full drug effects have become apparent.

In the treatment of acute exacerbations of multiple sclerosis daily intramuscular doses of 80-120 units for 2-3 weeks.

The chronic administration of more than 40 units daily may be associated with uncontrollable adverse effects.

When reduction in dosage is indicated this should be accomplished gradually by either reducing the amount of each injection, or administering injections at longer intervals, or by a combination of both of the above. During reduction of dosage, careful consideration should be given to the disease being treated, the general medical condition of the patient and the duration over which corticotropin was administered.

This product may be administered subcutaneously or intramuscularly.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
The invention relates to a composition for treating axillary osmidrosis and belongs to the technical field of traditional Chinese medicines. The composition is prepared from a mixture composed of following raw materials comprising iodine tincture, sharp red dry chilli, myrcia and folium artemisiae argyi and is prepared through following steps: uniformly mixing the raw materials, grinding the raw materials and sieving the raw materials for later use. The composition can be prepared into preparations, such as medicinal liquor, a water decoction, an ointment and the like. The composition is simple in components. The raw materials are easy to obtain. The composition is low in cost, has an astringent and drying effects, can avoid hidropedesis, has effects of inhibiting and killing bacteria and is better in deodorizing effects with comparison with a composition in the prior art. The composition is free of medicine taking, injection, intravenous drip and the like and is free of operative treatment in hospital.
Patients were treated with PFLL regimen: 5-fluorouracil intravenous infusion at 200mg/m2/d for 30 continuous days and intravenous infusion of platinum (cisplatin 70 mg/m2 or nedaplatin 80/m2 or lobaplatin 30 mg/ m2) on day 1 and day 28, every 60 days. Local treatment, molecular-targeted or immune checkpoint therapy, and supportive treatment were allowed.